1034467-80-5

Basic information

• Product Name: 5-cyclopropyl-2-fluoropyridine
• Synonyms: 5-cyclopropyl-2-fluoropyridine;5-Cyclopropyl-2-flluoropyridine
• CAS NO: 1034467-80-5
• Molecular Formula: C₈H₈FN
• Molecular Weight: 137.1542232
• Mol File: 1034467-80-5.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 5-cyclopropyl-2-fluoropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-cyclopropyl-2-fluoropyridine(1034467-80-5)
• EPA Substance Registry System: 5-cyclopropyl-2-fluoropyridine(1034467-80-5)

Safety Data

• Hazardous Substances Data: 1034467-80-5(Hazardous Substances Data)

Usage

General Description

5-cyclopropyl-2-fluoropyridine is a chemical compound with the molecular formula C7H6FN. It is a pyridine derivative with a cyclopropyl group and a fluorine atom attached to the second position of the pyridine ring. 5-cyclopropyl-2-fluoropyridine is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. It possesses unique chemical and physical properties due to the presence of the cyclopropyl and fluorine substituents, making it a valuable intermediate in organic chemistry. Its structural features make it a promising candidate for drug design and development, particularly in medicinal chemistry and drug discovery research.

Upstream product

• 171197-80-1 2-fluoro-5-iodopyridine 
• 411235-57-9 cyclopropylboronic acid 
• 766-11-0 5-bromo-2-fluoropyridine 

Relevant articles and documents

PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (A), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatmen

PYRAZOLE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS

The present invention relates to compounds of formula (I) for their use in the treatment and/or prevention of auto-immune or auto-immune related diseases, cancer, viral infections, and central nervous system diseases and disorders, by inhibiting human deh

IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER

The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. Formula I wherein: R1 is aminomethyl, (C1-C3 alkyl)aminomethyl, di(C1-C2 alkyl)aminomethyl, N- ethyl-N-methyl-aminomethyl, 1-aminoethyl, 1-((C1-C2 alkyl)amino)-ethyl, 3,3,3- trifluoropropylaminomethyl, ethynyl, 2-hydroxy-ethoxy, 2-hydroxyethylaminomethyl, 2- cyanoethylaminomethyl, mopholin-4-ylmethyl, methoxymethoxymethyl, cyclopropyl, 1- azetidinylmethyl, 1-pyrrolidinylmethyl, or 1,3-dioxolan-2-yl; R2 is hydrogen or halo; R3 is hydrogen or halo; provided that at least one of R2 and R3 is hydrogen; R4 is hydrogen, methyl, or halo; and is a single bond that is either present or absent, or a pharmaceutically acceptable salt thereof.